Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Serplulimab (Primary) ; Carboplatin; Pemetrexed
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASTRUM-002
  • Sponsors Shanghai Henlius Biotech

Most Recent Events

  • 25 Jul 2025 According to Henlius Biopharmaceuticals media release, results from this trial will be presented in an oral presentation at the 2025 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC) to be held from September 6-9 in Barcelona, Spain.
  • 12 Dec 2023 According to a Henlius Biopharmaceuticals media release, the National Medical Products Administration (NMPA), has accepted for NDA serplulimab, in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC), based on results from this trial.
  • 07 Aug 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top